6-Methyl-indolizin-carbonsaeure-(2) | 103264-06-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 6-Methyl-indolizin-carbonsaeure-(2)
• 英文别名: 6-methyl-indolizine-2-carboxylic acid；6-methylindolizine-2-carboxylic Acid
• CAS: 103264-06-8
• 化学式: C₁₀H₉NO₂
• 分子量: 175.187
• InChiKey: REPVCDVWDWGIQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  41.7
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'UNE INFECTION À ARÉNAVIRUS
  申请人：ARISAN THERAPEUTICS INC

  公开号：WO2016160677A1

  公开（公告）日：2016-10-06

  The present invention relates to the use of piperazinones for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Bolivian, Argentine, Venezuelan, Brazilian, Chapare and Lujo hemorrhagic fevers, to methods of inhibiting the replication of arenaviruses, to methods of reducing the amount of arenaviruses, and to compositions that can be employed for such methods.

  本发明涉及使用哌嗪酮类化合物抑制人类、其他哺乳动物或细胞培养中的病毒感染，用于治疗拉沙病、玻利维亚病、阿根廷病、委内瑞拉病、巴西病、查帕雷病和卢霍出血热等病毒感染的方法，用于抑制病毒复制的方法，用于减少病毒数量的方法，以及可用于这些方法的组合物。
• SUBSTITUTED 2-AMINO-CYCLOALKANECARBOXAMIDES AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1453801A1

  公开（公告）日：2004-09-08
• [EN] SUBSTITUTED 2-AMINO-CYCLOALKANECARBOXAMIDES AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] 2-AMINO-CYCLOALKANECARBOXAMIDES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA CYSTEINE PROTEASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003048123A1

  公开（公告）日：2003-06-12

  The present invention relates to compounds of formula (I) wherein R?l, R2, R3, R4, R5, R6¿ and n are as defined in the description and claims and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for the treatment of diseases which are associated with cysteine proteases such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis, atherosclerosis, myocardial infarction, angina pectoris, instable angina pectoris, stroke, plaque rupture, transient ischemic attacks, amaurosis fugax, peripheral arterial occlusive disease, restenosis after angioplasty and stent placement, abdominal aortic aneurysm formation, inflammation, autoimmune disease, malaria, ocular fundus tissue cytopathy and respiratory disease.